The golden days for some drugs in China seem to be passing, and manufacturers are preparing to battle sizzling competition by raising cash and focusing more on profitable innovative therapies as demand for such products rises.
US giant Eli Lilly & Co. has seemingly become the latest multinational pharma firm to decide to divest maturing products in this market, against a background of intense competition for some of its past core products
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?